Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | timothy.power@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 30000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Sometimes some things work, and sometimes other things work...
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
Company recently showed positive data in cancer and graft versus host disease.
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).
CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Highlights for the week that ESMO 2018 began. Oncology news had important implications for investors across the space
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | timothy.power@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 30000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Sometimes some things work, and sometimes other things work...
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
Company recently showed positive data in cancer and graft versus host disease.
Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)
AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).
CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share
Expansion of 2016 deal to evaluate Infinity PI3K-gamma inhibitor in combination with BMY's Opdivo (Image: Infinity Pharmaceuticals)
Highlights for the week that ESMO 2018 began. Oncology news had important implications for investors across the space
| Last Price 60.79 | Change $ -0.35 | Change % -0.57 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 61.01 | High 61.66 | Low 60.59 | Prev Close 61.14 |
| Last Trade | Volume 9.2 mi | 52 Wk Hi 68.34 | 52 Wk Low 42.48 |
| Market Cap 137.5 bi | Ex-Div Date | Div Rate 1.80 | Yield 2.9610 |
| Shares 2,262,689,755.00 | EPS (TTM) 0.62 | PE Ratio 98.00 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 9 | 156 |
| Number of Buys | 5 | 95 |
| Number of Sells | 4 | 61 |
| Net Activity | 14249 | 331983 |
| Last 10 Buys | Shares |
|---|---|
| Dinesh C. Paliwal | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| James M. Cornelius | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Thomas J. Lynch | 1,000 |
| Sandra Leung | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Louis S. Schmukler | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Louis S. Schmukler | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 72 | 72 | 72 | 72 |
| Low Target Price Estimate | 47 | 47 | 47 | 47 |
| Mean Target Price Estimate | 60.55 | 60.91 | 60.91 | 60.55 |
| Standard Deviation | 7.88 | 8.19 | 8.19 | 7.88 |
| Date of Most Recent Estimate | 06/05/18 | 05/23/18 | 05/14/18 | 06/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2018-04-26 |
| 8-K | Report of unscheduled material events or corporate changes. | 27 | 2018-04-26 |
| DEFA14A | Additional proxy soliciting materials - definitive | 15 | 2018-04-23 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-05 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 |
| Moderate Buy | 0 | 0 | 1 | 1 |
| Hold | 8 | 7 | 6 | 6 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 |
| Mean Rec. | 2.23 | 2.08 | 2.18 | 2.1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait